Ann: ATL1102 DMD Paediatric Investigation Plan submitted to EMA, page-31

Hey coolgrace

Short term if it goes in the direction I have mentioned on the correct deal being done,
I would say $2 -$2.50

Coolgrace if and I say if this trial is a success on both sides then the only gauge we have is Sarepta so long term this going to market we could see the stock in excess of $12 - $25
or
$5 - $12 bil MC

You can only go by comparison and just at this moment in time we are making

Sarepta look like a pretty sad case and they topped out with a market cap of around $15bil

Look at the possibilities if we chase all indications where CD49D is a marker

$$$$$$

We are half way there with RRMS and they are talking of moving into the unmet field of SPMS another massive market which should spill into both the RRMS and SPMS fields

Plus us plus

But we are getting ahead off ourselves here

The value creation is there we just have to be steered in the correct direction and extract that value to the max

We are in the driving seat

And should deal as such

This is not a ramp anyone that understands where we are at, will acknowledge my statement is not cuckoo land

I am not talking tomorrow here

let's not forget for all the above we are struggling to hold 18c here and now

See how we go